Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bluejay Diagnostics (BJDX) Cash & Equivalents (2021 - 2023)

Bluejay Diagnostics' Cash & Equivalents history spans 3 years, with the latest figure at $2.2 million for Q4 2023.

  • On a quarterly basis, Cash & Equivalents fell 78.17% to $2.2 million in Q4 2023 year-over-year; TTM through Dec 2023 was $2.2 million, a 78.17% decrease, with the full-year FY2023 number at $2.2 million, down 78.17% from a year prior.
  • Cash & Equivalents hit $2.2 million in Q4 2023 for Bluejay Diagnostics, down from $5.1 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for BJDX hit a ceiling of $19.0 million in Q4 2021 and a floor of $2.2 million in Q4 2023.
  • Historically, Cash & Equivalents has averaged $10.5 million across 3 years, with a median of $10.1 million in 2022.
  • Biggest five-year swings in Cash & Equivalents: tumbled 46.9% in 2022 and later plummeted 78.17% in 2023.
  • Tracing BJDX's Cash & Equivalents over 3 years: stood at $19.0 million in 2021, then tumbled by 46.9% to $10.1 million in 2022, then plummeted by 78.17% to $2.2 million in 2023.
  • Business Quant data shows Cash & Equivalents for BJDX at $2.2 million in Q4 2023, $5.1 million in Q3 2023, and $5.1 million in Q2 2023.